U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H10N2O4
Molecular Weight 198.176
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIMOSINE

SMILES

N[C@@H](CN1C=CC(=O)C(O)=C1)C(O)=O

InChI

InChIKey=WZNJWVWKTVETCG-YFKPBYRVSA-N
InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)/t5-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26610453 | https://www.ncbi.nlm.nih.gov/pubmed/10047457 | https://www.ncbi.nlm.nih.gov/pubmed/25957199

Mimosine or leucenol is an alkaloid, beta-3-hydroxy-4 pyridone amino acid. Mimosine is an effective inhibitor of DNA replication in mammalian cells. It blocks entry into S phase (late G1 phase), and suppress elongation of DNA replication (S phase). The chelation of iron seems to be one of the main modes of action of mimosine for cell cycle arrest. As an iron-chelating and cell cycle stopping agent, mimosine was tested in preclinical models of cancer, pulmonary fibrosis and iron overload.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Centrosome duplication proceeds during mimosine-induced G1 cell cycle arrest.
2008-04
S-phase progression stimulates both the mutagenic KU-independent pathway and mutagenic processing of KU-dependent intermediates, for nonhomologous end joining.
2008-03-13
Cell cycle related modulations in Runx2 protein levels are independent of lymphocyte enhancer-binding factor 1 (Lef1) in proliferating osteoblasts.
2007-10
Differential regulation of iron chelator-induced IL-8 synthesis via MAP kinase and NF-kappaB in immortalized and malignant oral keratinocytes.
2007-09-13
Mimosine mitigates oxidative stress in selenium deficient seedlings of Vigna radiata. Part II: mitochondrial uptake of 75selenium and mimosine.
2007-09
Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest.
2007-08
Mimosine mitigates oxidative stress in selenium deficient seedlings of Vigna radiata--Part I: Restoration of mitochondrial function.
2007-07
The pydA-pydB fusion gene produces an active dioxygenase-hydrolase that degrades 3-hydroxy-4-pyridone, an intermediate of mimosine metabolism.
2007-06
Studies on cell-cycle synchronization in the asexual erythrocytic stages of Plasmodium falciparum.
2007-03
Determination of growth inhibitory action point of interferon gamma on WISH cells in cell cycle progression and the window of responsiveness of the cells to the interferon.
2007-02
Cell cycle-dependent association of Rad51 with the nuclear matrix.
2007-01
Overexpression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay.
2007-01
Expression and actions of HIF prolyl-4-hydroxylase in the rat kidneys.
2007-01
Cell cycle arrest drastically extends the duration of gene silencing after transient expression of short hairpin RNA.
2006-10
Selective determination of mimosine and its dihydroxypyridinyl derivative in plant systems.
2006-10
FAT10, a gene up-regulated in various cancers, is cell-cycle regulated.
2006-09-08
Tyrosinase inhibition studies of cycloartane and cucurbitane glycosides and their structure-activity relationships.
2006-09-01
Piperidones with activity against Plasmodium falciparum.
2006-08
Distinctive activities of DNA polymerases during human DNA replication.
2006-07
Elevated phosphorylation of Chk1 and decreased phosphorylation of Chk2 are associated with abrogation of G2/M checkpoint control during transformation of Syrian hamster embryo (SHE) cells by Malachite green.
2006-06-18
The susceptibility of granulosa cells to apoptosis is influenced by oestradiol and the cell cycle.
2006-06
Polyamine depletion and cell cycle manipulation in combination with HSV thymidine kinase/ganciclovir cancer gene therapy.
2006-06
The mitotic manipulation of cytotrophoblast differentiation in vitro.
2006-03-06
Newt orthologue of Growth arrest-specific 6 (NvGas6) is implicated in stress response during newt forelimb regeneration.
2006-03
Activation of the human FP prostanoid receptor disrupts mitosis progression and generates aneuploidy and polyploidy.
2006-01
Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428.
2005-11-15
Antidermatophytic and bacterial activity of mimosine.
2005-11
Goniothalamin induces cell cycle-specific apoptosis by modulating the redox status in MDA-MB-231 cells.
2005-10-17
Modulation of differentiation-related gene 1 expression by cell cycle blocker mimosine, revealed by proteomic analysis.
2005-07
Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines.
2005-06-21
Structure-activity relationships of tyrosinase inhibitory combinatorial library of 2,5-disubstituted-1,3,4-oxadiazole analogues.
2005-05-16
Induction of hypoxia inducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells.
2005-05
Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling.
2005-03
Inhibition of MCP-1 and MIP-2 chemokines in murine trichinellosis: effect of the anti-inflammatory compound L-mimosine.
2005-02-09
Iron-mediated H2O2 production as a mechanism for cell type-specific inhibition of tumor necrosis factor alpha-induced but not interleukin-1beta-induced IkappaB kinase complex/nuclear factor-kappaB activation.
2005-01-28
Mimosine attenuates serine hydroxymethyltransferase transcription by chelating zinc. Implications for inhibition of DNA replication.
2005-01-07
P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine.
2005
Progesterone receptor and the cell cycle modulate apoptosis in granulosa cells.
2004-11
Cell cycle arrest at the initiation step of human chromosomal DNA replication causes DNA damage.
2004-10-01
A novel nucleolar protein, PAPA-1, induces growth arrest as a result of cell cycle arrest at the G1 phase.
2004-09-29
Human hRad1 but not hRad9 protects hHus1 from ubiquitin-proteasomal degradation.
2004-07-01
Response of ADA and its isoenzymes in mice infected by Trichinella spiralis and treated with mimosine.
2004-06-03
Cytotoxic activity of deferiprone, maltol and related hydroxyketones against human tumor cell lines.
2004-05-27
Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth.
2004-05-06
AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression.
2004-04-09
Do calcium-mediated cellular signalling pathways, prostaglandin E2 (PGE2), estrogen or progesterone receptor antagonists, or bacterial endotoxins affect bovine placental function in vitro?
2004-04
Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol.
2004-01-01
Mimosine, a plant-derived amino acid induces apoptosis in human pancreatic cancer xenografts.
2003-12-12
Replication inhibitors modulate instability of an expanded trinucleotide repeat at the myotonic dystrophy type 1 disease locus in human cells.
2003-11
DNA breaks induction by mimosine.
2003-10-28
Patents

Sample Use Guides

In model of pulmonary fibrosis mimosine was administed at doses 25 and 50 mg/kg. Pulmonary fibrosis was induced by tracheal instillation of 5 mg/kg bleomycin. Mimosine was first dissolved in Tris-buffer at pH 8.9, and then pH was adjusted to 7.2 with 1 N HCl. Before administration, this solution was freshly diluted by 0.9% physiologic saline to achieve the required concentration. L-Mimosine was administered via subcutaneous injection once daily from day 1 to day 28 after BLM or saline treatment.
Route of Administration: Other
The effect of mimosine on asynchronously proliferating HeLa cells was analyzed by flow cytometry. HeLa-S3 cells were cultured as proliferating monolayers on 145-mm plates in DMEM, supplemented with 10% FCS, 10 U/ml penicillin, and 0.1 mg/ml streptomycin. Mimosine stock solution was prepared at 10 mM in DMEM and filtered through 20-mm filters. Synchronization of HeLa cells by mimosine was achieved by adding mimosine from the stock solution directly to the cells at the concentrations specified. Cell synchronization was determined by flow cytometry of isolated nuclei. One million nuclei were directly stained with propidium iodide (5 mg/ml in PBS containing 0.4% Triton X-100) and analyzed by FACScan (Becton Dickinson) using the Lysis II-software.
Name Type Language
MIMOSINE
MI  
Common Name English
NSC-69188
Preferred Name English
Mimosine [WHO-DD]
Common Name English
LEUCENOL
Common Name English
L-MIMOSINE
Common Name English
MIMOSIN
Common Name English
MIMOSINE [MI]
Common Name English
1(4H)-PYRIDINEPROPANOIC ACID, .ALPHA.-AMINO-3-HYDROXY-4-OXO-, (.ALPHA.S)-
Systematic Name English
LEUCAENOL
Common Name English
LEUCENINE
Common Name English
LEUCAENINE
Common Name English
Code System Code Type Description
CHEBI
29063
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
DRUG CENTRAL
1811
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
FDA UNII
Z46B1LUI5N
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
PUBCHEM
440473
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
EPA CompTox
DTXSID401017244
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
DRUG BANK
DB01055
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
ECHA (EC/EINECS)
207-905-1
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
MERCK INDEX
m7550
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY Merck Index
NSC
69188
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
HSDB
3512
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
CHEBI
77689
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY
CAS
500-44-7
Created by admin on Mon Mar 31 22:46:47 GMT 2025 , Edited by admin on Mon Mar 31 22:46:47 GMT 2025
PRIMARY